Amyotrophic lateral sclerosis
Mitsubishi Tanabe Pharma Canada, Inc.
Call for patient/clinician input open:
Call for patient/clinician input closed:
NOC Status at Filing:
Manufacturer Requested Reimbursement Criteria1:
For the treatment of amyotrophic lateral sclerosis (ALS)
For the treatment of amyotrophic lateral sclerosis (ALS).
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.